

This article was downloaded by:[Academy of Sciences of China]
On: 8 April 2008
Access Details: [subscription number 788769980]
Publisher: Taylor & Francis
Informa Ltd Registered in England and Wales Registered Number: 1072954
Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Journal of Asian Natural Products Research

Publication details, including instructions for authors and subscription information:
<http://www.informaworld.com/smpp/title~content=t713454007>

Speciosaperoxide, a new triterpene acid, and other terpenoids from *Chaenomeles speciosa*

Ya-Ling Song^a; Li Zhang^b; Jin-Ming Gao^c; Guan-Hua Du^b; Yong-Xian Cheng^a

^a State Key Laboratory of Phytochemistry and Plant Resources in West China,

Kunming Institute of Botany, The Chinese Academy of Sciences, Kunming, China

^b Institute of Materia Medica, Chinese Academy of Medical Sciences, Beijing, China

^c Natural Products Resource Research Centre, College of Life Sciences, Northwest A and F University, Yangling, China

Online Publication Date: 01 March 2008

To cite this Article: Song, Ya-Ling, Zhang, Li, Gao, Jin-Ming, Du, Guan-Hua and Cheng, Yong-Xian (2008) 'Speciosaperoxide, a new triterpene acid, and other terpenoids from *Chaenomeles speciosa*', Journal of Asian Natural Products Research, 10:3, 214 - 217

To link to this article: DOI: 10.1080/10286020701395370

URL: <http://dx.doi.org/10.1080/10286020701395370>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article maybe used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

Speciosaperoxide, a new triterpene acid, and other terpenoids from *Chaenomeles speciosa*

Ya-Ling Song^{ab}, Li Zhang^c, Jin-Ming Gao^b, Guan-Hua Du^c and Yong-Xian Cheng^{a*}

^aState Key Laboratory of Phytochemistry and Plant Resources in West China, Kunming Institute of Botany, The Chinese Academy of Sciences, Kunming 650204, China; ^bNatural Products Resource Research Centre, College of Life Sciences, Northwest A and F University, Yangling 712100, China; ^cInstitute of Materia Medica, Chinese Academy of Medical Sciences, Beijing 100050, China

(Received 2 November 2006; final version received 10 February 2007)

Investigation on the EtOH extract of the fruits of *Chaenomeles speciosa* led to the isolation of a new triterpene acid bearing an unusual hydroperoxyl substitute group at C-11, speciosaperoxide (**1**), along with six known triterpenoids, 3 β -acetoxyurs-11-en-13 β ,28-olide (**2**), 3-*O*-acetyl ursolic acid (**3**), oleanolic acid (**4**), ursolic acid (**5**), masilinic acid (**6**), and tormentic acid (**7**), and three known norsesquiterpenoids, roseoside (**8**), vomifoliol (**9**) and (6*S*,7*E*,9*R*)-6,9-dihydroxy-4,7-megastigmadien-3-one 9-*O*-[β -D-xylopyranosyl (1 \rightarrow 6)-glucopyranoside] (**10**). Their structures were elucidated on the basis of spectroscopic data and comparison with reference data. Besides compound **1**, compounds **2**, **8–10** were obtained from this genus for the first time. None of these compounds exhibited inhibitory activity against T- and B-lymphocyte proliferation.

Keywords: *Chaenomeles speciosa*; Rosaceae; peroxide triterpene acid; norsesquiterpenoid; lymphocyte proliferation

1. Introduction


Disease prevention is increasingly becoming a public concern of modern healthcare.¹ Nature manufactures a great deal of diverse structures that may serve as nutraceuticals providing medical or health benefits including the treatment and prevention of disease. Edible plants containing nutrients, dietary supplements or secondary metabolites may play an essential role in preventing the incidence of cardio- and cerebrovascular diseases, cancer and various chronic diseases.² *Chaenomeles speciosa* (Sweet) Nakai (Rosaceae) is a shrub originally growing in China, whose matured fruits are used as both famous herbal medicine for the treatment of rheumatism and arthritis as well as widespread foods.^{3–5} Previous investigation revealed that amino acids, carbohydrates, proteins, organic acids, phenolics, triterpenoids and their glycosides and vitamin C are the main components.^{6–12} To explore additional secondary metabolites and extend our understanding of their structural features and roles in rheumatoid arthritis disease, a phytochemical investigation followed by bioassay was performed, and ten terpenoids were obtained. Among them, compound **1** was a novel triterpene acid with an unusual hydroperoxyl group at C-11; compounds **2**, **8–10** were first isolated from this genus. All of these isolates showed no inhibitory effect on T- and B-lymphocyte proliferation.

2. Results and discussion

The dried fruits of *Chaenomeles speciosa* were extracted with 95% EtOH and partitioned with petroleum ether, EtOAc in H₂O. A combination of normal phase and gel chromatography of petroleum ether extract afforded a new peroxide triterpene acid, speciosaperoxide (**1**), along with six triterpenoids 3 β -acetoxyurs-11-en-13 β ,28-olide (**2**),¹³ 3-*O*-acetyl ursolic acid (**3**),^{14,15} oleanolic acid (**4**),¹⁶ ursolic acid (**5**),^{14,15} masilinic acid (**6**),¹⁷ tormentic acid (**7**),¹⁸ and three norsesquiterpenoids, roseoside (**8**),¹⁹ vomifoliol (**9**)²⁰ and (6*S*,7*E*,9*R*)-6,9-dihydroxy-4,7-megastigmadien-3-one 9-*O*-[β -D-xylopyranosyl (1 \rightarrow 6)-glucopyranoside] (**10**)²¹ (Figure 1).


Compound **1** was isolated as a white oily solid. The molecular formula was determined as C₃₂H₅₀O₆ by HRFAB-MS and ¹³C NMR and DEPT experiments. The ¹H NMR spectrum distinctly exhibited five singlet methyl groups (δ 0.81, 0.86, 0.88, 1.07, 1.17), two doublet methyl groups (δ 0.96, d, *J* = 4.4 Hz; 0.98, d, *J* = 4.4 Hz), one acetoxy group (3H, δ 2.05, s), and one olefinic proton (δ 5.48, d, *J* = 3.3 Hz, H-12). The ¹³C NMR and DEPT spectra showed signals for two carbonyl groups (δ 171.0 and 182.7), a double bond (δ 144.6 and 125.5), and two oxygenated carbons (δ 81.2 and 80.5). Comparison of these data with those of compound **3** indicated that the main difference between them was that a sp³ methylene in **3** was replaced by an oxygenated sp³

*Corresponding author. Email: yxcheng@mail.kib.ac.cn

Figure 1. Structures of compounds **1–10**.

methine at δ 81.2, this oxygen bearing position was considered to be C-11 by the key HMBC correlations (Figure 2) of H-11 at δ 4.51 with C-9, 10, 12 and 13. A very downfield chemical shift of C-11 at δ 81.2 in **1** instead of δ 68.3 of C-11 in 3 β -acetoxy-11 α -hydroxy-12-ursene²² supported the presence of a hydroperoxyl

group at C-11 in **1** instead of a hydroxyl group. Further comparison of the NMR spectral data of **1** with those of 3 β -acetoxy-11 α -hydroxyperoxy-12-ursene²² indicated that they bore the same substitute group at C-11, the main difference was the CH₃-17 in 3 β -acetoxy-11 α -hydroxyperoxy-12-ursene was substituted by COOH-17

Figure 2. Important NOESY (\leftrightarrow) and HMBC (\rightarrow) correlations for **1**.

in **1**, which hence led to the downfield shift of C-17 (from δ 33.6 to δ 47.4), and upfield shifts of C-16 (from δ 27.8 to δ 23.8), C-18 (from δ 58.4 to δ 51.9), and C-22 (from δ 41.3 to δ 36.5). A positive brown colour reaction of **1** with 1% KSCN-FeSO₄ reagent provided additional evidence for the existence of a hydroperoxyl moiety in **1**, although a downfield proton signal for active hydroperoxyl group was not detected in both DMSO-*d*₆ and CDCl₃. The proton of H-11 was positioned at a β -axial orientation because of the presence of NOESY correlations (Figure 1) of H-11 with CH₃-25 and CH₃-26. H-3 was assigned as α -orientation by comparison of ¹H NMR and ¹³C NMR data with those of **3**. Taken together, the structure of compound **1** was elucidated as 3 β -acetoxy-11 α -hydroperoxy-12-ursen-28-oic acid.

The common functionality group at C-11 of ursane- and oleanane-type triterpenoids is ketone or hydroxyl. The hydroperoxyl group substitute at this position like compound **1** is unusual, and few similar examples have been isolated from *Ficus microcarpa*.^{23,24} Amongst the five species of the genus *Chaenomeles*, only the fruit of *C. speciosa* is accepted by Chinese pharmacopoeia and considered as quality standard. Our present study indicated that as compounds **1**, **2**, **8–10** were first isolated from this genus, these components may be also related with the quality of *C. speciosa*.

Considering the medical uses of this herb relative with inflammation and immune response and *in vivo* experimental results on immunoregulatory activity of the total glucosides,²⁵ an *in vitro* anti-proliferation assay against T and B lymphocytes was conducted in this study. Unfortunately, none of the isolates showed an inhibitory effect. Does the *in vivo* activity result from metabolic forms of these compounds or from other secondary metabolites present in total glucosides? This question could not be answered here.

3. Experimental

3.1 General experimental procedures

Optical rotation was measured on a P-1020 Polarimeter (JASCO, Tokyo, Japan). 1D and 2D NMR experiments were recorded in pyridine-*d*₅ or CDCl₃ on Bruker AM-400 and DRX-500 spectrometers with tetramethylsilane as the internal standard. Coupling constants are expressed in Hertz and chemical shifts are given on a δ (ppm) scale. FAB-MS and HRFAB-MS spectra were recorded on a VG Auto Spec-3000 (Micromass UK Ltd., Manchester) magnetic sector instrument. Column chromatography was performed on 200–300 mesh silica gel and silica gel H (Qingdao Marine Chemical Factory, China), Sephadex LH-20 (25–100 μ m, Amersham Pharmacia Biotech AB) and RP-18 (40–63 μ m, Daiso

Co., Ltd., Japan). Fractions were monitored by thin-layer chromatography (TLC), with visualisation under UV (254 or 365 nm) or spots staining by spraying with 10% sulphuric acid in ethanol or anisaldehyde reagent, followed by heating.

3.2 Plant material

The dried fruits of *Chaenomeles speciosa* (Sweet) Nakai were commercially purchased from Yunnan Pharmaceutical Co. Ltd., Yunnan Province of China, in March 2005, and identified as *C. speciosa* by Mr Hong-Yan Sun. A voucher specimen (No. 00117) has been deposited at the State Key Laboratory of Phytochemistry and Plant Resources in West China, Kunming Institute of Botany, China.

3.3 Extraction and isolation

The dried fruits of *C. speciosa* (5 kg) were extracted with 95% EtOH under reflux three times (3 \times 10 L). The combined EtOH extracts were evaporated to dryness *in vacuo* and suspended in water followed by partition with petroleum ether and EtOAc. The petroleum ether soluble extracts (18 g) were chromatographed on a silica gel column (900 g, 200–300 mesh) eluting with petroleum ether/EtOAc of increasing polarity, and four fractions were combined based on their TLC patterns. Repeated chromatography of fraction 1 over silica gel (10–40 μ m) column with petroleum ether/*i*PrOH (50:1) as eluent yielded compound **3** (38 mg). Compounds **1** (4 mg) and **2** (18 mg) were purified from fraction 2 by repeated column chromatography over silica gel (10–40 μ m) and Sephadex LH-20 (25–100 μ m) eluting with MeOH. The EtOAc soluble substance was dried to give 120 g of extract, an aliquot of which (50 g) was subjected to a silica gel column (2500 g, 200–300 mesh) eluting with CHCl₃/MeOH mixtures of increasing polarity to afford six fractions. Repeated column chromatography over silica gel, Sephadex LH-20 and RP-18 (40–63 μ m) afforded compounds **4** (10 mg) and **8** (11 mg) from fraction 1, compounds **5** (9 mg) and **6** (7 mg) from fraction 2, compounds **7** (23 mg) and **9** (15 mg) from fraction 3, **10** (31 mg) from fraction 4, respectively.

3.3.1 *Speciosaperoxide (1)*

White oily solid; $[\alpha]_D^{23} + 8.3$ (*c* 0.0055, CHCl₃); UV (CHCl₃) λ_{\max} (log ϵ): 241 (3.16) nm; IR (KBr) ν_{\max} (cm⁻¹): 3426, 2923, 2853, 1734, 1691, 1640, 1461, 1369, 1252, 1033; ¹H NMR (400 MHz, CDCl₃) δ : 2.10 (2H, m, H-1), 4.52 (1H, m, H-3), 0.90 (1H, m, H-5), 1.84 (1H, d, *J* = 8.8 Hz, H-9), 4.51 (1H, m, H-11), 5.48 (1H,

Table 1. ^{13}C NMR spectral data of **1** in CDCl_3 (100 MHz, δ in ppm).

Position	δ_{C}	Position	δ_{C}
1	39.0	17	47.4
2	23.6	18	51.9
3	80.5	19	38.6
4	37.8	20	38.6
5	55.2	21	30.4
6	18.1	22	36.5
7	33.2	23	28.1
8	42.7	24	16.6
9	49.1	25	16.7
10	37.9	26	18.6
11	81.2	27	22.4
12	125.5	28	182.7
13	144.6	29	17.1
14	41.9	30	21.3
15	29.7	CH_3CO	171.0
16	23.8	CH_3CO	21.1

d, $J = 3.3$ Hz, H-12), 2.28 (1H, d, $J = 11.2$ Hz, H-18), 1.78 (2H, m, H-22), 0.86 (3H, s, H-23), 0.88 (3H, s, H-24), 1.07 (3H, s, H-25), 0.81 (3H, s, H-26), 1.17 (3H, s, H-27), 0.96 (3H, d, $J = 4.4$ Hz, H-29), 0.98 (3H, d, $J = 4.4$ Hz, H-30), 2.05 (3H, s, CH_3CO); ^{13}C NMR (100 MHz, CDCl_3): see Table 1; FAB-MS (negative mode): m/z 529 $[\text{M} - \text{H}]^-$; HRFAB-MS m/z : 529.3524 $[\text{M} - \text{H}]^-$ (calcd for $\text{C}_{32}\text{H}_{49}\text{O}_6$, 529.3529).

3.4 Assay for lymphocyte proliferation

Lymphocytes were isolated from the spleen of Balb/c mice. Proliferation of lymphocytes was analysed *in vitro* using an MTT colorimetric assay.²⁶ Lymphocytes were seeded in 96-well microculture plates at a cell density of 1×10^5 per well. T- and B-lymphocyte activation was induced by concanavalin A and lipopolysaccharide (final concentration 5 $\mu\text{g}/\text{ml}$, 15 $\mu\text{g}/\text{ml}$), respectively. A dose/response curve was drawn up using different concentrations of compounds **1–10**. Final concentrations of test compounds in the assay were 0.625, 1.25, 2.5, 5, and 10 $\mu\text{g}/\text{ml}$. Wells containing cyclosporine A (50 nM) and Medium 1640 were as positive and negative controls, respectively. All assays were carried out in duplicate. After 72 h of incubation, MTT reagent (final concentration of 4 mg/ml) was added and the cells were cultured for 4 h, then the cells were dissolved in dimethyl

sulphoxide. Spectrophotometric measurement was carried out at 540 nm using a microplate reader.

Acknowledgements

We would like to express our thanks to the members of the Analytical Centre of our laboratory for the measurements of all spectral data. This work was supported in part by a grant named Xi-Bu-Zhi-Guang scholarship from the Chinese Academy of Sciences.

References

- A.D. Weston and L. Hood. *J. Proteome Res.* **3**, 179 (2004).
- P.A. Cerutti. *Science* **227**, 375 (1985).
- E. Lesinska, R. Przybylski, and N.A.M. Eskin. *J. Food Sci.* **53**, 854 (1988).
- X.F. Xie, X.Q. Cai, S.Y. Zhu, and G.L. Zou. *Food Chem.* **100**, 1312 (2007).
- Jiangsu New Medical College. *Zhongyao Dacidian* (Shanghai Science and Technology Publishing House, Shanghai, China, 1977), p. 349.
- R.L. Chen, T.J. Wu, and Y.J. Dai. *West China J. Pharm. Sci.* **15**, 38 (2000).
- Z.M. Zheng and S.Y. Wang. *Fujian J. Tradit. Chin. Med.* **16**, 325 (1985).
- C.L. Guo, C.B. Tian, and S.H. Tang. *Chin. Med. J.* **64**, 689 (1984).
- M. Dai, W. Wei, Y.X. Shen, and Y.Q. Zheng. *Acta Pharmacol. Sinica* **24**, 1161 (2003).
- Z.R. Jing. *Chin. Herb. Med. Bull.* **6**, 18 (1975).
- H.Y. Gong, H. Wang, and Z. Xu. *Pharmacol. Clin. Chin. Mater. Med.* **2**, 30 (1995).
- H.C. Chen, L.S. Ding, S.L. Peng, and X. Liao. *Chin. Tradit. Herb. Drugs* **36**, 30 (2005).
- A. Ikuta, H. Tomiyasu, Y. Morita, and K. Yoshimura. *J. Nat. Prod.* **66**, 1051 (2003).
- L.N. Sun, Y.F. Hong, X.M. Guo, G.J. Yang, and G.M. Zhang. *Acad. J. Sec. Mil. Med. Univ.* **20**, 752 (1999).
- L.N. Sun and Y.F. Hong. *J. Chin. Pharm. Sci.* **9**, 6 (2000).
- X.M. Guo, Y.F. Hong, and L. Zhang. *Chin. Tradit. Herb. Drugs* **28**, 584 (1997).
- H.Y. Gao, L.J. Wu, and M. Kuroyanagi. *Chin. J. Nat. Med.* **1**, 82 (2003).
- H.Y. Gao, B. Wu, W. Li, D.H. Chen, and L.J. Wu. *Chin. J. Nat. Med.* **2**, 351 (2004).
- Y. Champavier, G. Comte, J. Vercauteren, D.P. Allais, and A.J. Chulia. *Phytochemistry* **50**, 1219 (1999).
- S.S. Bina, M.N. Kardar, T. Ali, and S. Khan. *Hel. Chim. Acta.* **86**, 2164 (2003).
- M. Noriko, I. Kyouko, and K. Masao. *Phytochemistry* **45**, 777 (1997).
- Y.H. Kuo and Y.M. Chiang. *Chem. Pharm. Bull.* **48**, 593 (2000).
- Y.M. Chiang and Y.H. Kuo. *J. Nat. Prod.* **64**, 436 (2001).
- Y.M. Chiang and Y.H. Kuo. *J. Nat. Prod.* **63**, 898 (2000).
- Q. Chen and W. Wei. *Int. Immunopharmacol.* **3**, 593 (2003).
- Y.K. Qian. *Practical New Immunology Technology* (Peking University Medical Press, Beijing, China, 1994), p. 11.